Homocysteine serum level and eye affection in Behҫet's disease patients
Senara, S., Fathy, H., Abd El- Khalek, M., Mohamed, R., Tantawy, M. (2022). Homocysteine serum level and eye affection in Behҫet's disease patients. EKB Journal Management System, 3(2), 253-265. doi: 10.21608/ejmr.2022.244218
Soha Senara; Hossam Fathy; Mohammed Othman Abd El- Khalek; Rabab Afifi Mohamed; Marwa Tantawy. "Homocysteine serum level and eye affection in Behҫet's disease patients". EKB Journal Management System, 3, 2, 2022, 253-265. doi: 10.21608/ejmr.2022.244218
Senara, S., Fathy, H., Abd El- Khalek, M., Mohamed, R., Tantawy, M. (2022). 'Homocysteine serum level and eye affection in Behҫet's disease patients', EKB Journal Management System, 3(2), pp. 253-265. doi: 10.21608/ejmr.2022.244218
Senara, S., Fathy, H., Abd El- Khalek, M., Mohamed, R., Tantawy, M. Homocysteine serum level and eye affection in Behҫet's disease patients. EKB Journal Management System, 2022; 3(2): 253-265. doi: 10.21608/ejmr.2022.244218

Homocysteine serum level and eye affection in Behҫet's disease patients

Egyptian Journal of Medical Research
Article 18, Volume 3, Issue 2, April 2022, Page 253-265  XML PDF (896.08 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2022.244218
View on SCiNiTO View on SCiNiTO
Authors
Soha Senara1; Hossam Fathy2; Mohammed Othman Abd El- Khalek3; Rabab Afifi Mohamed4; Marwa Tantawy2
1Rheumatology Department, Fayoum University, Fayoum, Egypt
2Rheumatology Department, Beni Suef University, Beni Suef, Egypt
3Ophthalmology Department, Beni Suef University, Beni Suef, Egypt
4Clinical Pathology Department, Beni Suef University, Beni Suef, Egypt
Abstract
Background: Vascular endothelial dysfunction represents the major pathogenesis abnormalities in Behçet’s disease (BD). Homocysteine (Hcy), a non-protein-forming amino acid was proposed to be involved in the inflammatory process, and increasing homocysteine concentrations in ischemia may lead to leukocyte recruitment in the affected tissue.  Aim: to find out the possible relation between homocysteine (HCY) serum level and ocular involvement in Behçet’s disease (BD) patients. Methods: 30 BD patients as classified by the new International Behçet's Disease Criteria (25 males and 5 females with the age mean 33.83 ± 9.41years) and 20 healthy control subjects (age and sex matched) were included. The patients were divided into two groups: those with BD and eye involvement (n=24) and those without ocular involvement (n= 6).  Results:  The mean serum HCY values in BD patients were substantially greater than in healthy controls (37.87 ± 10.31 and 21.80 ± 5.47 mmol/L, respectively; P <0.001). HCY readings were higher in patients with eye involvement than in patients who did not have eye involvement. (38.91 ± 10.13 and 33.72 ± 10.9 mmol/L, respectively) yet, these differences did not reach the level of statistical significance (P>0.278). Conclusion: Serum HCY level is increased in BD. No association was found between HCY levels and eye involvement. Because hyperHCY is a treatable risk factor, measurement and monitoring of HCY levels may be a valuable index in the investigation, management and improving the outcome of patients with BD.
Keywords
Behçet’s disease; homocysteine; Eye involvement
References
  1. Fouad NA, Ahmed TI., Shaker OG, Abdelaleemd OO:  Relation of ischemia-modified albumin to disease manifestations and activity in Egyptian patients with Behçet’s disease. Egypt Rheumatol Rehabil 2019; 46: 108–112. https://doi.org/10.4103/err.err_66_18 .
  2. Alpsoy E,      Leccese  p, Emmi G and   Ohno S: Treatment of Behçet's Disease: An Algorithmic Multidisciplinary Approach. MINI REVIEW article. Front. Med., 28 April 2021 | https://doi.org/10.3389/fmed.2021.624795.
  3. Alpsoy E, Bozca BC , Bilgic A: Behçet Disease: An Update for Dermatologists. Am J Clin Dermatol 2021;  22, 477–502 . https://doi.org/10.1007/s40257-021-00609-4.
  4.  Özyazgan Y and Bodaghi B : Eye Disease in Behçet’s Syndrome. In Yazıcı Y and Yazıcı H (eds) Behcet’s Syndrome. Springer New York Dordrecht Heidelberg London 2010; 5: 73-94.  
  5. Yücel  C ,    Omma   A,    Sertoğlu   E ,    Sezer   S ,    Turhan   T,    Özgürtaş    T :  Evaluation of atherogenic laboratory markers in Behçet’s disease patients with vascular involvement. Arch Med Sci 2020;16(3):531–537.  DOI: https://doi.org/10.5114/aoms.2018.79139
  6. Evereklioglu C, Er H, Tȕrköz Y, et al : Serum levels of TNF-α, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet’s disease. Mediators of Inflammation 2002;11, 2: 87–93. doi: 10.1080/​09629350220131935
  7. Er H, Evereklioglu C, Cumurcu T,  et al : Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behҫet’s disease. British Journal of Ophthalmology 2002; 86 (6): 653–657. DOI:10.1136/bjo.86.6.653
  8. Lee YJ, Kang SW, Yang JI, et al : Coagulation parameters and plasma total homocysteine levels in Behcet’s disease. Thrombosis Research 2002; 106: 1: 19–24. doi: 10.1016/s0049-3848(02)​00085-3.
  9. Upchurch GR Jr, Welch GN, Fabian AJ, et al : Homocysteine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997;272:17012–17017. This paper is available on line at http://www.jbc.org
  10. Bogdanski P, Pupek-Musialik D, Dytfeld J, et al : Plasma homocysteine is a determinant of tissue necrosis factor-α in hypertensive patients. Biomedicine and Pharmacotherapy 2008; 62 (6): 360–365. https://doi.org/10.1155/2008/407972 
  11. Yesilova Z, Pay S, Oktenli C, et al: (2005) Hyperhomocysteinemia in patients with Behҫet’s disease: is it due to inflammation or therapy?” Rheumatology International 2005; 25 (6): 423–428.  doi: 10.1007/​s00296-004-0466-9
  12. Davatchi F, Assaad-Khalil S, Calamia KT, et al : The International Criteria for Behcet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol 2014; 28(3): 338-47.  doi: 10.1111/jdv.12107.  
  13. Knapp RG, Miller MC. Clinical epidemiology and biostatistics. Published by Williams &​ Wilkins; Malvern, Pa. : Harwal Pub. Co., C.
  14. McHugh J :  Different phenotypes identified for Behçet syndrome. Nat Rev Rheumatol 2021; 17, 188 . https://doi.org/10.1038/s41584-021-00587-1
  15. Cansu DU, Kasifoglu T, Korkmaz C : Do clinical findings of Behcet's disease vary by gender?: A single-center experience from 329 patients. Europ J Rheumatol. 2016; ;3(4):157-60. [DOI:10.5152/eurjrheum.2016.038] 
  16. Davatchi F, Shahram F and Chams-Davatchi C :  Behcet’s disease: is there a gender influence on clinical manifestations? International Journal of Rheumatic Diseases 2012; 15(3): 306–314.   doi: 10.1111/j.1756-185X.2011.01696
  17. Aksu K, Turgan N, Oksel F , et al :  Hyperhomocysteinaemia in Behҫet’s disease. Rheumatology 2001; 40 (6): 687–690. https://doi.org/10.1093/rheumatology/40.6.687.
  18. Korkmaz C, Bozan B, Kosar M, et al :  Is there an association of plasma homocysteine levels with vascular involvement in patients with Behçet's syndrome? Clin Exp Rheumatol 2002; 20 (26):30-34. https://doi.org/10.1161/ATVBAHA.110.207068
  19. Houman H, Feki M, Ghorbel I B, et al :  Does hyperhomocysteinemia increase the risk of thrombosis in Behҫet’s disease?. Advances in Experimental Medicine and Biology 2003; 528, 413–417.  DOI:10.1155/2010/361387    https://doi.org/10.1007/978-1-4419-5641-5_5.
  20. Ates A, Aydintug O, Olmez U,  et al :  Serum homocysteine level is higher in Behçet’s disease with vascular involvement. Rheumatol Int 2005; 25(1):42–44. https://doi.org/10.1007/s00296-003-0398-9
  21. Sarican T, Ayabakan H, Turkmen S,  et al :  Homocysteine: an activity marker in Behҫet’s disease? Journal of Dermatological Science 2007; 45 (2): 121–126. DOI:10.1016/j.jdermsci.2006.11.008
  22. Elbay AE, Topalkara A, Elbay A, et al : Evaluation of Serum Homocysteine and Leptin Levels in Patients with Uveitis. Turk J Ophthalmol2015; 45: 146-151. doi: 10.4274/tjo.26539.
  23. Hamzaoui A, Chelbi H, Sassi FH and Hamzaoui K :  Release of B cell-activating factor of the TNF family in bronchoalveolar lavage from Behçet’s disease with pulmonary involvement. Oxid Med Cell Longev 2010;. 3:122–8. doi: 10.4161/oxim.3.2.11149.
  24. Aflaki E, Mehryar M, Nazarinia MA,  et al : The Relation between serum homocysteine level and eye involvement in Behçet’s disease. Arch Iranian Med 2008; 11 (6): 625 – 628. : https://www.researchgate.net/publication/23443584
  25. Allam A, Ammar H and Radwan A :  Serum homocysteine level and eye involvement in Egyptian patients with Behҫet’s disease. The Egyptian Rheumatologist 2014;  36, 29–34. http://dx.doi.org/10.1016/j.ejr.2013.09.002
  26. Ates A, Aydintug O, Olmez U , et al : Serum homocysteine level is higher in Behçet’s disease with vascular involvement. Rheumatol Int 2005; 25(1):42–44. https://doi.org/10.1007/s00296-003-0398-9
 

Statistics
Article View: 270
PDF Download: 135